Benitec Biopharma Inc.
- Last sale
- Nov 12, 2026 · -4.10%
- Market cap
- $329.41M
- 36.12M shares
- Filings
- 336
Q3 2026−100.0% FY24 yoy
Q1 2027N/M FY26 yoy
Q1 2027N/M FY26 yoy
FY 2026derivedN/M FY26 yoy
Q1 2027N/M FY26 yoy
Q1 2027+84.1% FY26 yoy
- $329.41M
- —
- —
- 1.9×
- -5.05%
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2024 | 2024-06-30 | $0 | reported | |
| FY 2023 | 2023-06-30 | $75,000 | reported | |
| FY 2022 | 2022-06-30 | $73,000 | reported | |
| FY 2021 | 2021-06-30 | $59,000 | reported | |
| FY 2020 | 2020-06-30 | $102,000 | reported | |
| FY 2019 | 2019-06-30 | $12,199,000 | reported |
Segments
Products
LineFY2024ShareChange
Licensing revenue$0.00—−100.0%
Royalty revenue———
Service revenue———
Total$0.00
Pharmaceutical preparations
Benitec Biopharma Inc. is the 214th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
PEPGPepGen Inc.———$350.5MCYDYCytoDyn Inc.———$338.0MAVIRAtea Pharmaceuticals, Inc.———$330.0M
BNTCBenitec Biopharma Inc. (this company)———$329.4M
ENTAEnanta Pharmaceuticals IncFiscal 2025 figures$65.3M3.4%125.4%$325.8MGALTGalectin Therapeutics Inc———$314.7MALTAltimmune, Inc.$41.0K105.0%214,861.0%$312.3MTTRXTurn Therapeutics Inc.———$310.0MEBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR